Guangdong epidemic situation: According to a report by China News Service on August 10th, the Guangdong Provincial Bureau of Disease Control and Prevention released information that from 0:00 on August 3rd to 24:00 on August 9th, the province reported 1387 new local cases of chikungunya fever, with no severe or fatal cases reported. The cases are distributed in Foshan (1212 cases), Guangzhou (103 cases), Zhanjiang (39 cases) and other places. The rapid rise of the epidemic in Foshan City has been initially contained, and the number of newly reported cases in the province has shown a continuous downward trend. However, due to the wide impact of the epidemic, the risk of imported cases continues to exist, and the frequent mosquito activities during the flood season, epidemic prevention and control cannot be relaxed.

Characteristics and hazards of chikungunya fever: According to the "2025 Global Clinical Management Guidelines for Arboviruses" released by the World Health Organization, the incubation period of chikungunya fever is usually 4-8 days. Symptoms are obvious when the disease occurs, and patients often present with fever and joint pain, as well as muscle pain, headache, fatigue, rash, and nausea and vomiting. Joint pain often starts from the small joints of the hands and feet, and is symmetrically distributed. In severe cases, it can affect daily activities. About 30% of patients will experience long-term joint stiffness and discomfort, and elderly people over 65 years old, chronic disease patients, and newborns are more likely to develop into severe cases.

The transmission route of Chikungunya fever: Chikungunya fever is a viral disease transmitted through the bite of Aedes mosquitoes, with Aedes aegypti and Aedes albopictus being the main vectors of transmission. After human infection, high titer viremia can occur within 2-5 days after onset, and being bitten by mosquitoes can easily cause virus transmission.

Prevention and treatment of chikungunya fever: Currently, there is no specific antiviral drug for chikungunya fever worldwide, mainly relying on symptomatic supportive treatment such as fever reduction and pain relief. The key to prevention lies in clearing stagnant water, eliminating mosquitoes, and preventing bites, such as lighting mosquito coils, hanging mosquito nets, installing screen windows, and clearing stagnant water in every household. In February 2025, the US FDA approved Vimkonya (recombinant vaccine for chikungunya fever) injection, suitable for individuals aged 12 and above, using virus like particle (VLP) technology as a single dose vaccine.